intake several times and found that the estimate of relative risk based on the most recent measurement or on a cumulative measure was greater than that based on the first measurement of consumption. 4 Subjects who had a high risk were recommended to have a further examination and intervention, if appropriate. For men the percentage referred increased with increasing coffee consumption, whereas for women it by and large decreased. Accordingly, the intervention may have weakened the relation between coffee consumption and death from coronary heart disease in men and strengthened it in women.
The major uncertainty relating to previous studies has been whether the apparent relation between coffee and death from coronary heart disease is mediated through correlated lifestyle factors. We took physical activity and stress into consideration, but we have no information about socioeconomic status. As regards diet, a cross sectional study of the first Oppland survey carried out five years before the Oppland part of this study showed that dietary habits and lifestyle could not explain the association of coffee and serum cholesterol concentration,'0 and a follow up relating dietary habits and lifestyle to death from coronary heart disease has not yet been done.
We conclude that coffee consumption is fairly strongly related to death from coronary heart disease, but a potential causal role is weakened by the varying strength of the relation in different groups. To verify the observed effect of coffee on deaths from coronary heart disease over and above the effect on cholesterol concentration, cholesterol concentration must be determined more accurately than by a single measurement. Results-Follow up data were available for 670 patients. The procedure was technically successful in 611 patients (88%). The overall cure rate for hypertension was 24% (163 patients) and a further 43% (286) were "improved." There were large and significant variations between studies in the rate of technical success and also the blood pressure outcome. In each series patients with fibromuscular lesions, had a higher cure rate than those with atherosclerotic lesions (overall cure 50% v 19% odds ratio 3-9, 95% confidence interval 2-6 to 6.0). Complications were reported in 63 (9%) patients and three patients died (0-4%).
Conclusions -The evidence for the value of angioplasty in treating renovascular hypertension has serious limitations. Angioplasty for fibromuscular disease seems to be worth while, but for atherosclerotic lesions the benefit appears to be small and its efficacy needs to be compared with medical therapy in randomised trials. These BMJ VOLUME 300 lished. We present here an overview of the findings in these series and assess the evidence for the efficacy and safety of the procedure.
Methods
We searched published reports up to the end of 1987 to identify series of hypertensive patients who had renovascular disease treated by angioplasty. Small series, arbitrarily defined as those with fewer than 30 patients, were excluded because a low success rate in centres with limited experience of the procedure would bias the findings against angioplasty. Those which included only specialised cases -for example, children or patients who had undergone transplantation-were also excluded, as were series which were incomplete because they did not account for technical failures. When more than one series had been reported from a single centre only the largest series was included in the analysis. Ten series were identified which fulfilled these criteria.'-" ' We extracted information on the protocol and findings of each study. When available, we sought the following items of information: protocols-selection criteria, measurement of blood pressure, follow up schedule, policy for adjusting antihypertensive drugs, use of prophylaxis against restenosis or thrombosis, definitions of cure and improvement; findingsnumber of patients in whom angioplasty was attempted, number of technically successful dilatations, the blood pressure response as categorised by the authors, measurements of renal function, the number and nature of any complications.
Results

PROTOCOLS
Selection cnrteria
The criteria used for selecting patients for angioplasty varied widely between these series. There was no uniformity in the degree of stenosis or the need for renal vein renin measurements. For example, three studies included patients with greater than 50% stenosis,3 " while another included only patients with greater than 75% stenosis plus abnormal renal vein renin values. 4 One centre included patients with angiographic evidence of stenosis of any degree, provided that there was lateralisation of renal vein renin values.' In another the decision was made after a multidisciplinary discussion of the results of a number of investigations.' Four reports gave no selection criteria at all.' 26 Furthermore, none of the papers described the population from which the patients were drawn.
Blood pressure methods and follow up Most reports gave little information about the follow up of patients, particularly with regard to the measurement of blood pressure. In four series follow up appeared to have been conducted according to a defined schedule at the centre which performed the procedure.' In three series, however, follow up blood pressure measurements were obtained elsewhere -for example, by writing or telephoning the patient or referring physician." "' Three reports did not state how or where the follow up measurements were obtained.
Drug policies
The reports gave little information about policies for adjusting antihypertensive drug treatment before or after angioplasty. In one centre antihypertensive drugs were stopped immediately before the procedure to avoid precipitous falls in blood pressure."' The criteria for reintroducing treatment were not stated. Another report stated that patients had their usual drugs continued, reduced in dosage, or discontinued depending on the blood pressure response and also stated that alternative drugs were not used.' The other reports gave no information about changes in antihypertensive drug treatment.
Prophylaxis against restenosis or thrombosis after angioplasty was used in all but ones series,' but the regimens varied. These included aspirin and dipyridamole,2 "' aspirin alone,46 aspirin or warfarin,9 and coumarin.3
Definitions ofcure and improvement ofhypertension
In all studies the definition of cure of hypertension after angioplasty required that the patient had been able to stop taking all antihypertensive drugs. In five centres cure was defined as a diastolic blood pressure of 90 mm Hg or less.'-4"' In two further centres the proviso was added that diastolic blood pressure had to have fallen by 10 mm Hg or more from values before angioplasty.; Three reports used both systolic and diastolic criteria,6"9 as follows: <140/90 mm Hg6; <150/95 mm Hg'; <160/95 mm Hg.9 It is not clear whether either or both systolic and diastolic blood pressure had to have reached these levels.
The various definitions of "improvement" in blood pressure used in this series are shown in ed series of than for those with atheromatous stenosis (combined odds ratio 3-9, 95% confidence interval 2 6 to 6-0; figure) . The overall cure rates were 50% in fibro--__ muscular disease and 19% in atherosclerotic disease. Hypertension was cured by angiopiasty :n 163 patients (24%), and it was said to be improved ir. a further 286 (43%/)'. One third of al patients were iuaged to have received no benefit. There was large variation between studies in blood pressure response, and these differences would not be expected by chance (x2=71-3; df= 18; p<0001). In examining the reason for this, we found that the oropertions of patlents categorised. as improved (21-67%) and faled (7.54%) varie(l greatly, .lthough the cure rate was fairly uniform (rarnge 15-34%).
To see whether or not these va;iacLor s mighr. be explaine_ by diffeiences in the type of lesion treazed, we ex-.mined sept rately patients wlth atheromato-is .lnd fibromuscula' tenoses. Foir mriost paients whose angioplasty was a techinical failure the type of stenosis was not given. These patients and those who were not followed up (91 in total) were excluded from this analysis. The results in these two main diagnostic groups are rhown in table III. In all 10 series the cure rate was higher for patients with fibromuscular stenosis Sixty three complications were reported in 691 patients (9-1%). Three were fatal (cholesterol embolism, cerebral haemorrhage, bowel infarction), a rate of 4 3 deaths per 1000 patients. According to the classification of Mahler et al," 56 complications (89%) were direct and seven (11%) indirect. It was not possible to determine from the reports the proportions of complications which were major and minor. Those most frequently reported were renal artery dissection (14) , renal artery thrombosis or occlusion (10), segmental renal infarction (7), and haematoma formation or puncture trauma (7). The indirect complications were cerebrovascular accidents (3), myocardial infarction (1), anterior spinal artery thrombosis (1), brachial artery thrombosis (1) , and bowel infarction (1).
Discussion
There have been no randomised trials comparing transluminal angioplasty for renovascular hypertension with surgical or medical treatment. Nevertheless, angioplasty is genera'ly accepted to be as effective as surgery but simpler and safer, and it is increasingly Log odds ratios and 95% confidence intervals Log odds ratios (0) and 95% confidence intervals ( ) for cure rates for fibromuscular versus atherosclerotic disease in 10 series of hypertensive patients treated by renal artery angioplasty. An odds ratio greater than I indicates a higher success rate in fibromuscular disease BMJ VOLUME 300 3 MARCH .99C
I regarded as the treatment of choice. The pooled results of published case series purport to show that hypertension was cured in a quarter of patients while one third obtained no benefit. To what extent the remaining patients did benefit from angioplasty is uncertain, mainly because these studies were uncontrolled, and "improvement" in blood pressure could have occurred spontaneously in a substantial proportion of patients. 2 Patients whose hypertension was cured by angioplasty still needed regular follow up plus prophylactic medication against restenosis. Because of the possibility of publication bias, these findings may overestimate the true benefit from angioplasty -that is, series with findings unfavourable to the procedure may have been less likely to have been published. The studies reviewed also had several important weaknesses. The selection criteria were generally ill defined, and the patients studied were probably highly selected, which could have biased the findings in favour of angioplasty. Most studies were conducted in tertiary referral centres and their results may not be widely generalisable to unselected populations. There was significant variation in the technical failure rate between centres. This difference was probably due to selection factors rather than variation in technical skill.
There were also large differences between studies in the proportions of patients classified as improved or failed. Given the multiplicity of definitions of improvement in blood pressure (table I), this was hardly surprising. Definitions of cure were more uniform and cure rates varied much less. Other factors which may have accounted for differences in blood pressure outcome include manipulation of antihypertensive drugs and methods for evaluating the blood pressure response. Most of the follow up blood pressure data were inadequate because no attempt was made to prevent measurement bias, formal follow up schedules were not used, and policies on drug treatment were non-existent. An important part of the benefit from angioplasty is likely to be a treatment sparing effect,'" but these studies did not document it.
The papers included in our overview also did not include enough data to permit an adequate assessment of the effect of angioplasty on renal function. Two studies apparently showed significant improvement in renal function, but the absence of data for some patients may have been a source of bias.9"1 Two papers published very recently provide relevant data on this point. In a study of atherosclerotic patients renal function after angioplasty was unchanged in the long term.9 Because there was no comparator group, it is uncertain to what extent this finding represents a benefit. Of 79 patients with renovascular disease of various causes accompanied by pre-existing renal insufficiency or deteriorating renal function, 34 (43%) had a reduction in serum creatinine concentration of 20% or more during a mean follow up period of 16 months after angioplasty.'4 Overall, a beneficial effect of angioplasty on renal function has not been convincingly established.
The pooled analysis of 10 studies supports the view that the outcome of renal artery angioplasty depends on the type of stenosis treated. In all studies cure rates were higher for fibromuscular disease than for atherosclerotic disease. In patients whose angioplasty was technically successful the overall cure rate in fibromuscular disease was 50%. Despite our reservations about the methods of these studies, we do not doubt that angioplasty for fibromuscular disease is worth while.
In atheromatous disease the cure rate after technically successful angioplasty was only 19%. In completely unselected patients atherosclerotic lesions are associated with a very high rate of technical failure, perhaps as much as 60%. '2The true cure rate might therefore be as low as 8%. It is not certain whether such a small benefit is worth while, especially as atherosclerotic patients seem to be particularly susceptible to important complications.49 In atherosclerotic stenosis there is a need for randomised comparisons of angioplasty against standard medical treatment. Until such studies have been performed, angioplasty for atherosclerotic lesions is difficult to justify since the small benefit might well be outweighed by the risks.
We are critical of the haphazard and unscientific way in which angioplasty has been evaluated. There is a sharp contrast in the quality of data that is acceptable for evaluation between a theoretically attractive practical procedure such as angioplasty and a new drug. If these data had been used to support the efficacy of an antihypertensive drug, no regulatory body would have found them acceptable.
Technological advances in many different aspects of medical practice will continue to emerge, and if we are to avoid practising on the basis of fashion a more organised and critical approach to evaluation must be adopted. Choosing the right moment to perform controlled experiments is difficult because the technology and skill usually improve rapidly in the early years. This does not mean, however, that proper trials can be dispensed with. Such trials need to be scientifically rigorous and pragmatic both in design and assessment of outcome. Carefully chosen selection criteria are essential so that the findings will be broadly applicable to general populations.
